At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Apr 13, 2026 at 07:00 ET
Ocular Therapeutix presented additional Week 52 post-hoc data from its SOL-1 Phase 3 trial for AXPAXLI, an investigational therapy for wet AMD, demonstrating superior durability and sustained disease control compared to aflibercept. The company remains on track to submit an NDA based on SOL-1 alone, pending formal discussions with the FDA, aligning with recent FDA commentary supporting single-trial approval pathways.
- AXPAXLI showed a median time to ≥30 μM CSFT increase of 39 weeks vs. 16 weeks for aflibercept, a 23-week difference (hazard ratio 0.7, p=0.0028).
- Median time to ≥75 μM CSFT increase was 46 weeks for AXPAXLI vs. 24 weeks for aflibercept (hazard ratio 0.5, p<0.0001).
- 81% of AXPAXLI subjects were rescue-free at Week 24; 75% remained rescue-free at Week 36.
- Visual acuity gains from the loading phase were maintained through Week 52 across BCVA quartiles.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access